Exelixis Inc (EXEL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $16.84B
Last updated: Nov 17, 2026 at 11:05 AM ET
Exelixis Inc (EXEL) Competitors
The companies most similar to Exelixis are BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO) and Summit Therapeutics (SMMT). Exelixis trades at 19.3x earnings, against a median of 27.7x for the 3 of these companies with a P/E. By market cap, Exelixis ranks 5th of the 13 companies on this page; Revolution Medicines (RVMD) is the largest at $37.27B.
Peer Comparison
EXEL's revenue growth of 10.2% is below the peer median of 50.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Exelixis (EXEL) | $16.84B | 19.3x | 6.9x | 35.4% | N/A | 10.2% | 0.00% |
| BridgeBio Pharma Inc (BBIO) | $15.25B | N/A | 16.0x | -59.8% | -33.0% | 192.6% | 0.00% |
| Halozyme Therapeutics Inc (HALO) | $11.43B | 17.8x | 6.1x | 26.9% | 15.8% | 39.2% | 0.00% |
| Summit Therapeutics PLC (SMMT) | $11.32B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Ascendis Pharma AS (ASND) | $18.06B | N/A | 13.5x | 72.9% | 12.4% | 73.0% | 0.00% |
| TG Therapeutics Inc (TGTX) | $9.75B | 87.2x | 11.1x | 11.8% | 11.0% | 60.7% | 0.00% |
| Spyre Therapeutics Inc. (SYRE) | $9.88B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Apogee Therapeutics, Inc. Common Stock (APGE) | $10.22B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Insmed Inc (INSM) | $26.58B | N/A | 17.7x | -39.9% | -44.2% | 268.4% | 0.00% |
| Roivant Sciences Ltd (ROIV) | $28.64B | N/A | 679.3x | 0.0% | N/A | 2136.0% | 0.00% |
| Protagonist Therapeutics Inc (PTGX) | $8.55B | 27.7x | 15.8x | 62.0% | N/A | 5724.0% | 0.00% |
| Revolution Medicines Inc (RVMD) | $37.27B | N/A | 181.6x | 0.0% | -52.1% | -95.2% | 0.00% |
| Vaxcyte Inc (PCVX) | $10.03B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $11.37B | 27.7x | 15.9x | 0.0% | -11.0% | 50.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Exelixis, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| BridgeBio Pharma Inc (BBIO) | BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. | BBIO competitors |
| Halozyme Therapeutics Inc (HALO) | Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. | HALO competitors |
| Summit Therapeutics PLC (SMMT) | Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America... | SMMT competitors |
| Ascendis Pharma AS (ASND) | Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark. | ASND competitors |
| TG Therapeutics Inc (TGTX) | TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development... | TGTX competitors |
| Spyre Therapeutics Inc. (SYRE) | Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by... | SYRE competitors |
| Apogee Therapeutics, Inc. Common Stock (APGE) | Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD)... | |
| Insmed Inc (INSM) | Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. | INSM competitors |
| Roivant Sciences Ltd (ROIV) | Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive... | ROIV competitors |
| Protagonist Therapeutics Inc (PTGX) | Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical... | PTGX competitors |
| Revolution Medicines Inc (RVMD) | Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted... | RVMD competitors |
| Vaxcyte Inc (PCVX) | Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. | PCVX competitors |
Frequently Asked Questions About EXEL
Who are Exelixis' main competitors?
The companies most similar to Exelixis include BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO), Summit Therapeutics (SMMT), Ascendis Pharma AS (ASND) and TG Therapeutics (TGTX), listed from the closest match.
Who is Exelixis' biggest competitor?
Revolution Medicines (RVMD) is the largest of the similar companies at $37.27B; BridgeBio Pharma (BBIO) is the closest match by business profile, size, sector and industry.
How does EXEL stock compare with its competitors?
EXEL's P/E is 19.3x against a peer median of 27.7x; its P/S is 6.9x against a peer median of 15.9x; its net margin is 35.4% against a peer median of 0.0%.
Which of Exelixis' competitors pays a higher dividend?
Exelixis pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Exelixis bigger than its competitors?
No. Exelixis is 5th by market cap among the 13 companies on this page; the largest is Revolution Medicines (RVMD) at $37.27B.
EXEL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors